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Introduction
Professor Shizuo Oi, thank you for introducing me and your
kind words. You have been my life-long friend and good to
me, both personally and professionally. Thank you, Charlie
and Genevieve Teo, for hosting this wonderful society meet-
ing in this beautiful city of Sydney, and John Kestle, for a
terrific scientific program.
Ladies and gentleman, it is a great honor for me to present
my presidential address here in this great city of Sydney in
front of my distinguished members and guests. This year
makes my 40th year in the profession of neurosurgery since
I started my career as a neurosurgery resident in 1972 at Kobe
University under Professor Satoshi Matsumoto. It coincides
with this year’s 40th annual meeting of International Society
for Pediatric Neurosurgery (ISPN). I was there in 1973 when
the first ISPN annual meeting was held in Keidanren Kaikan
Hall, Tokyo, Japan. Shizuo and I were assigned to the slide
projection team during the meeting, literally pushing the slide
cassettes upon the speaker’s request of “next slide please.”
Because the theme of this year’s annual meeting is
“Complications,” I thought it is a good opportunity to review
my published work, particularly those for pediatric posterior
fossa tumors, and share my experience with you to analyze if
what I did and observed were “right” or “wrong.” Often,
retrospective views provide a better perspective and guidance
to where we should navigate this most complex profession
into the future.
I have been fortunate to have mentors, Professors
Matsumoto and Anthony Raimondi in my professional life.
When I was still a naïve neurosurgery resident, they guidedme
toward this highly academic field of pediatric neurosurgery.
Exposure to my mentors’ activities and their philosophy, I set
my academic goals on three pillars: clinical service, education,
and research. My entire professional life where I worked on
these pillars was spent at Children’s Memorial Hospital which
changed its name to Ann & Robert H. Lurie Children’s
Hospital of Chicago after moving to a new beautiful facility
in downtown Chicago in June 2012. I have had terrific asso-
ciates, presently David, McLone, Arthur DiPatri, Robin
Bowman, and Tord Alden, over the past decade, running one
of the busiest pediatric neurosurgery services in North
America. In Children’s Memorial Hospital in Chicago, the
former chairmen, Luis Amador, Anthony Raimondi, and
David McLone, trained numerous pediatric neurosurgeons
who have been leaders in various parts of world. Keeping with
this tradition, I have trained many American and international
fellows and residents. Also, I am privileged to participate in
multiple international educational courses for pediatric neuro-
surgery sponsored by the ISPN Education Committee. I have
also emphasized the importance of basic research in pediatric
neurosurgery and pediatric brain tumors. At Children’s
Memorial Research Center (now Lurie Children’s Research
Center), I am very fortunate to have a Pediatric Neurosurgery
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Research Laboratory with Chandra Shekhar Mayanil, Ph.D. as
a leader over 12 years. Shekhar has done relentless efforts to
advance neurobiology research, neural tube defect in particu-
lar. In the same lab, we have conducted neurosurgical oncolo-
gy research with Guifa Xi, M.D., Ph.D., and Simone Sredni,
M.D., Ph.D. Falk Brain Tumor Research Program over the past
16 years of which I have been a director has focused on genetic
and epigenetic research presently under the leadership of Bento
Soares, Ph.D.
During my medical school years from 1966 to 1970, at
Kobe University, Kobe, Japan, neuroscience attracted me;
partly because I was fascinated by Frank Netter’s neuroanat-
omy book during my freshman year and of course because of
Ben Casey on the TV show in the mid-1960s. After graduat-
ing Kobe in 1970, I was accepted to be a rotating intern with
special emphasis on neurological surgery at St. Luke’s
International Hospital in Tokyo. It was that year of internship
that drew my interest to the care of children, particularly kids
with cancer. Two episodes that I encountered drove me to the
field of pediatric neurosurgery and brain tumor. One was a
10-year-old blind boy, Koh-chan, who had a large recurrent
cystic craniopharyngioma and was treated at St. Luke’s by
frequent Ommaya taps to drain the cyst. His symptoms
rapidly improved after each tap. But that was the only thing
that we could do, so I was told by my chief. Unfortunately, I
do not know what happened with Koh-chan after I left St.
Luke’s. Another one is a story written by a Japanese novelist,
Junichi Watanabe, about a young neurosurgeon’s devotion to
a boy with pontine glioma. It was televised in the evening, a
sort of soap opera, and the interns at St. Luke’s watched in the
dormitory. In that story, the young neurosurgeon attended this
poor child and watched helplessly his deterioration and ulti-
mate death like the fate of a snow flake. These were the
stories of 40 years ago, way before personal computer was
even imaginable. Now, I have to ask myself “Have we made
any progress in the outcome for children with these dreadful
brain tumors?”
Following my 2-year internship, I was accepted by
Professor Satoshi Matsumoto to become a neurosurgery resi-
dent and Ph.D. Candidate. Matsumoto had just arrived to
Kobe as the chairman of newly established Department of
Neurological Surgery. When I heard the news that Matsumoto
was to be the inaugural chairman of neurosurgery, I had no
hesitation to return to Kobe. Prior to that time, I researched
and learned that he was a trained pediatric neurosurgeon, the
first of its kind in Japan. At Kobe University, I spent my time
carrying on both clinical duties and hydrocephalus experi-
ments under his guidance. During that time, my interest in
pediatric neurosurgery grew, but most of the cases I took care
of were adult aneurysms and brain tumors. Two years later,
Professor Matsumoto arranged my residency training at
Northwestern University through his close friend Professor
Anthony Raimondi. Since my time at St. Luke’s, I always
wanted to study at the best center in the USA. The dream came
true and I started my residency in Chicago in July 1974.
Before leaving to Chicago, I read Raimondi’s textbook
Pediatric Neuroradiology and Matson’s Neurosurgery of
Infancy and Childhood, which were the only available text-
books for pediatric neurosurgery at that time.
In Chicago, Professor Raimondi kept me at Children’s
Memorial Hospital for two and a half years of my 6 years
residency for further exposure to pediatric neurosurgery.
Additionally, I had a 6-month rotation through Pediatric
Neurology at Children’s which was an absolute delight.
During that time, I learned how to examine neonates and
infants of which I essentially had no previous experience. In
1978, while I was chief resident at Children’s, Raimondi
offered me an attending job at Children’s Memorial Hospital
and Northwestern. I married Kathryn Bel Morley just before
the completion of my residency at the end of June 1980, and
then, we headed to New York, New York which was our
destination and honeymoon. I spent a 1 year of Cancer
Fellowship at Memorial Sloan-Kettering Cancer Center. In
July 1981, I returned to Chicago and joined my practice
with Raimondi, McLone, and Yoon S. Hahn at the
Children’s Memorial Hospital. Since then, I have had mul-
tiple partners who have come and gone except for Dave
McLone who continues his practice there. It was a great
honor for me to be appointed to be his successor as the
Chairman of Pediatric Neurosurgery at Children’s Memorial
Hospital after Dave relinquished the position in 2001.
Upon return to Chicago from New York in 1981, I was so
excited to be an attending neurosurgeon at this prestigious
institution and was curious for every aspect of pediatric neu-
rosurgery. Gradually, I concentrated my interest toward the
care of pediatric brain tumors. Professor Raimondi, then
Department Chair of Neurosurgery at Northwestern, appointed
me as a Center-wide Neuro-oncologist at Northwestern even
though I had little or no contact with adult patients. At
Children’s Memorial Hospital, recognizing that children with
brain tumors deserved more attention, I started Brain Tumor
Clinic in 1986, Multidisciplinary Brain tumor Board in 1988,
and Falk Brain Tumor Research Center in 1997. Together, they
became Falk Brain Tumor Center. During over 30 years at
Children’s Memorial, I was involved in the care of nearly
2,400 infants and children with brain tumors. When I started
my practice, the annual number of brain tumor patients was
only 25. However, over 30 years, it has increased by 4–5-folds
(Fig. 1). I am not sure of the cause of this steady increase of
pediatric brain tumors, perhaps due to improved diagnostic
methods, awareness of brain tumors among pediatricians, ex-
pansion of our market share, or some sort of environmental
factors.
Since I started my training in neurosurgery, I have witnessed
and enjoyed terrific advancement in technology. Before CT in
the 1970s, we, neurosurgery residents at Children’s Memorial,
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did a lot of pneumoencephalography and angiography under
sedation even for young infants. I was trained to perform
carotid and brachial angiography in Japan and Chicago, but
later learned how to perform femoral catheterization and angi-
ography. I enjoyed performing angiography and its interpre-
tations, then. Today’s patients are fortunate to not have to
undergo these invasive studies. Then, we were very meticu-
lous about indication of these invasive tests before CT era.
Careful history taking and neurological examinations were
mandatory. Now-a-days, the brain tumor diagnosis is done
readily; a technician would call me from CT or MR room
“Hey, Dr. T, come on over here, here is a huge tumor.” CTA
and MRA provide refined vascular anomalies without inva-
sive testing. Not only refined anatomical images are seen but
also functional localizations by functional MRI and diffusion
tensor imaging are readily available. New devises and tech-
nologies of neuroradiology field aid us in the operating room
as well. Image-guided neuro-navigational system has been
widely used, as well as replaced intraoperative ultrasonogra-
phy that we started to use 30 years ago [1]. We continue to use
intraoperative ultrasound from time to time. Vascularity of
vascular lesions is effectively reduced by interventional neu-
roradiologist, now using Onyx [2].
It was only in the late 1960s when surgical microscope
became available, but we have seen much advancement in
microneurosurgery since then. Surgical laser in the 1970s and
ultrasonic aspirator in the early 1980s changed the technique of
tumor resection from delicate parts of the brain and spinal cord.
Over the past 20 years, with improved endoscopic technology,
more and more cases have been managed by so-called mini-
mally invasive neurosurgery. Endoscopic third ventriculostomy
largely took over themanagement of obstructive hydrocephalus
[3]. Thanks to the development of advanced instrumentation,
some of the small intraventricular tumors can be removed by
neuroendoscopewithout craniotomy. Also, we have noted great
progress in pediatric anesthesia and critical care which has
provided us improved support in dealing with young patients’
brain surgery and postoperative care. When I was a resident in
the 1970s, it was not uncommon to experience cardiac arrest
during brain tumor resection in children, resulting in the need
for CPR.
We have done a better job in resecting tumors and even
massive cerebral hemispheric tumors have been resected [4].
Large extremely vascular choroid plexus papillomas in new-
born were resected successfully in spite of excessive blood
loss [5]. Regrettably, however, I lost three young patients
intraoperatively during my career as an attending surgeon: a
newborn with massive posterior fossa teratoma, a 3-month-
old infant with large hemispheric choroid plexus carcinoma,
and a 3-year-old boy with a massive third ventricle astrocy-
toma. The last two had sudden cardiac arrest following
tumor resection just before wound closure. I am still puzzled
about the exact cause of their cardiac arrest.
We have witnessed advancement in treating children with
brain tumor in other medical fields as well. One of them is
marked advancement in radiation oncology. There are big
shifts from classic orthogonal irradiation to image-guided
irradiation such as 3-D conformal, IMRT, proton radiation
and stereotactic radiosurgery.
As a neurosurgeon, I always wanted to irradiate the tumor
bed before wound closure. Late in the 1990s, a portable photon
radiation system was used by directly placing the tip of the
probe into the tumor. It was primarily practiced for metastatic
cancer. The same unit was used but with an applicator that fits
to the tumor resected cavity (INTRABEAM system) (Fig. 2).
We conducted a prospective study of intraoperative radiation
therapy (RT) to the tumor resected cavity. It started in 2001 as a
phase 1 study, and it included posterior fossa tumor as well.We
had a few terrific cases, particularly those of recurrent
ependymomas [6]. Partly due to conflict with national proto-
col, the accrual of patients for INTRABEAM trial was slow,
and we treated only 25 children over a 10 years’ time.
However, ultimately I noted the limitation of this therapy
because of unreliable dosimetry distribution along the tumor
resected cavity wall, the difficulty to bring it into deep seated
tumor bed through narrow opening, and the lack of response of
diffuse infiltrating tumor such as glioblastoma.
Chemotherapy has gained recognition for pediatric
brain tumor management since the 1980s. Various
chemoagents have been developed and used often with
a combination of multiple agents such as MOPP, eight
in one chemotherapy by Children’s Cancer Study group,
and baby POG protocol by Pediatric Oncology Group.
Over three decades, we have seen terrific responses of germ cell
tumors (except for teratomas) to chemotherapy. Chemotherapy
contributed to the improvement and quality of lives of children
Fig. 1 Annual number of patients with brain tumors over 30 years
treated at Children’s Memorial Hospital from 1981 to 2011. There were
2,398 infants and children. Note steady increase in numbers
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with medulloblastomas and also even those with benign
unresectable astrocytomas. More recently, infantile tumors are
treated with high-dose chemotherapy with stem cell rescue,
avoiding or delaying RT. Thanks to the recent advancements
in cancer biology, molecular targeted therapies have been
exercised largely on an experimental basis for the past 10 years.
These small molecule agents or monoclonal antibodies affect
more specific tumor cells and are less toxic to normal cells.
I used to resect chiasmal/hypothalamic astrocytomas and
regrettably often caused visual, endocrine, and neurological
problems in infants and children. Not many people believed
chemotherapy worked for benign astrocytomas until the late
1980s. However, chemotherapy became the first line of
treatment for these unresectable benign astrocytomas, since
then. Skeptically, we started this approach in 1988, but
behold, we attained 63 % recurrence-free survival at 5 years
[7]. Recent national study shows the result of 5-year event-
free survival as 45±3.2 % following chemotherapy alone,
less than we experienced [8]. But it is still better not to cause
surgical complications or radiation side effects in infants. At
least, chemotherapy provides some relief for the infant and
young child. It is delightful to see some children appear to
Fig. 2 INTRABEAM system
(a). Intraoperative photograph
showing irradiation to the
tumor resected cavity following
a removal of recurrent posterior
fossa ependymoma (b)
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be cured with chemotherapy. Discouragingly, however, it is
not uncommon to see a regrowth of initially responded
tumor a few years after discontinuing the treatment.
I wanted to improve the drug delivery system and have
been long interested in interstitial chemotherapy, a direct
administration to the tissue of brain tumors. Thus, I wrote
a review paper regarding this subject in 1991 for the
preparation of my future translational research and ulti-
mate clinical applications [9]. This convection enhanced
interstitial chemotherapy provides higher drug concentration
while circumventing the blood brain barrier through the ex-
tracellular spaces in the central nervous system. This approach
was intended to be applied to intrinsic unresectable tumors.
During my residency, I spent my time reviewing charts of
children with brain tumor at Children’s Medical Record
while taking every other night on call. I was mesmerized
doing the clinical review of these children, the majority of
whom I never met, yet I started to remember their names and
they felt like my own patients. Reviewing a ton of charts
provided me information as to how they presented, how
they were diagnosed and treated, and what their out-
comes were. The database I collected during that time
led to subsequent publications in the late 1970s and
early 1980s.
One of those publications is a paper concerning precraniotomy
shunts for hydrocephalus secondary to posterior fossa tumors
[10]. Hydrocephalus due to infratentorial tumors was initially
treated with a VP shunt, followed by tumor resection in sitting
position which was Dr. Raimondi’s idea. We waited 7 to 14 days
until papilledemawas resolved before posterior fossa craniotomy,
which was also his idea instead of craniectomy which was
popular at that time. This paper was unique because it
was one of the rare papers providing information as to when
the papilledema subsides. Nonetheless, I abandoned this
precraniotomy shunt approach. Since 1986 until now, I have
practiced ventriculostomy under the same general anesthesia
for posterior fossa craniotomy in prone position [11]. The
main concerns of precraniotomy shunting for a posterior fossa
tumor are the requirement of two general anesthesia and not
all patients necessarily need a shunt after successful tumor
resection. Also, post-shunt upward herniation is a real con-
cern. This upward herniation is usually seen in younger pa-
tients with medulloblastoma and ependymoma associated
with advanced hydrocephalus and occurs in 3–6 %. If it
occurs, it is absolutely devastating (Fig. 3).
Another subject that drew my interest was brain tumors
affecting infants [12, 13]. When compared the tumors dur-
ing the first year of life treated between 1952–1984 [13] and
more recent 1988–2010, it was only 1.8 per year in the
earlier experience while it was 5 per year in the later which
I presented at the annual meeting of ISPN in Goa, 2011
(Table 1). New pathological entity of atypical teratoid
rhabdoid tumor (ATRT) takes up a large part of malignant
tumors, which were very likely included in medulloblasto-
ma and PNET in the past.
Academic neurosurgeons must make an effort to contrib-
ute to the advancement in patient care and scientific discov-
ery in their own subspecialty. So, I did my share or have
tried to do so for pediatric neurosurgery and pediatric brain
tumor in particular. Here, I would like to share my own
experience with you by showing some of the brain tumor
research work that I was involved in. Because of the limited
time frame of this presidential address, I would like to go
over only a representative portion of posterior fossa tumors:
medulloblastoma, posterior fossa ependymoma, and brain
stem tumor.
Medulloblastomas
Early in my neurosurgical career, medulloblastoma attracted
my interest the most. It was because Dr. Raimondi invited me
to write a chapter of “IVth Ventricle Tumor” when I was a
resident for a new textbook Pediatric Neurosurgery [14].
Raimondi and I in 1979 published a paper emphasizing the
importance of radical resection ofmedulloblastoma [15]. Prior
to that time, biopsy followed by RT was an acceptable treat-
ment. The total resection group showed a better survival: 42%
after resection and 34.5% after incomplete resection at 5 years.
Please note they were treated in the pre-CT era so that we do
not know the time of recurrence, and the only thing we knew
then was dead or alive for survival statistics.
Medulloblastoma, however, is a challenging tumor to re-
move because of its proximity to the brain stem and cerebellar
peduncle. However, aggressive tumor resection can lead to
increased morbidity, particularly cerebellar mutism. A recent
data of my own, that were presented at ISPN [16], showed that
the incidence of cerebellar mutism among 100 consecutively
treated medulloblastomas was 24 %; it appears to be common
among children whose medulloblastoma has brainstem in-
volvement (32 %) or subtotal resection group (34 %) than
those without brainstem involvement (20 %) or total or near
total resection (19 %). A similar observation was presented by
Children’s Oncology Group (COG) prospective studies in
2006, in which 107, 24 %, of 450 children with medulloblas-
toma developed postoperative cerebellar mutism [17]. It was
comforting to note that I am not the only guy who is experienc-
ing such a high complication rate after all. Still the exact cause
of cerebellar mutism is not known. Hopefully, we can identify
the causes by DTI and find a method to avoid this devastating
complication.
We learned several things during follow-up of the radiation
sequelae on medulloblastoma in children. They are psychomo-
tor delay, second cancer, endocrinopathy, vasculopathy, hearing
loss, etc. [18, 19]. Raimondi and I wrote in 1979 one of the
earliest papers, warning about the concern of detrimental effects
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of ionizing radiation to the developing CNS among children
with medulloblastoma [20]. I think this is one of the most
important papers that I was involved in. A comparison was
made between medulloblastoma children who received RT (the
radiation dose to whole brain, 35 to 42 Gy) and cerebellar
astrocytoma children without RT. The IQ was far worse among
children with medulloblastoma. In the same year, Jean François
Hirsch from Paris published a similar observation [21].
Because of these observations, after discussing with our
radiation oncologists, we adopted a reduced craniospinal irra-
diation (CSI) dose to 25 Gy and published the data in 1986
[22]. We found there were no case mortalities during the
follow-up period of 24–67 months among the totally resected
group even though the dose was low. Both POG and CCG
incorporated this reduced-dose CSI RT protocol for the low-
stage medulloblastoma and compared two groups with CSI
dose 23.4 vs. 36 Gy, (randomizing 126 patients) without
chemotherapy [23]. Much to my dismay, however, it was
noted that the group with reduced dose showed higher
early relapse rates and disseminations, and the study was
closed in the very early stage. The data showed 67 %
event-free survival at 5 years among patients with stan-
dard radiation dose, whereas eligible patients receiving
reduced-dose CSI had 52 % event-free survival at 5 years
(P=0.080). Although long-term event-free survival rates
showed no statistical difference, it was concluded “The
5-year EFS for patients receiving reduced-dose irradiation
Fig. 3 Non-enhanced head CT
axial view showing a large
partially calcified tumor in the
cerebellum and advanced
hydrocephalus in an 8-month-
old infant (a). The infant
suddenly developed respiratory
arrest and coma about 10 h after
CSF diversion. Non-enhanced













Germ cell tumor 3 3
Hemangioma of infancy 0 3
Craniopharyngioma 2 0
Others 9 6
57 (1.8/year) 111 (5/year)
a Tomita and McLone [13]
b Tomita T, ISPN Goa, 2011
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is suboptimal, and improved techniques and/or therapies are
needed. Chemotherapy may contribute to this improvement.”
Together with Dr. Marianne Marymont of Northwestern
Radiation Oncology, we treated patients with medulloblastoma
with hyperfractionated RT, twice a day radiation, as a pilot
study and published the results in 1996 [24]. These patients
were treated with RT alone. This was a pilot study where we
noted that it was feasible but very labor intensive as you can
imagine, so we abandoned this approach and then long forgot
it. However, I was surprised to find these recent publications
using hyperfractionated radiation for medulloblastomas. A
French study using 36 Gy to CSI and 68 Gy to posterior fossa
without chemotherapy attained 75% 6-year event-free survival
rates [25]. They observed annual full scale IQ decline was 2
points over a 6-year period. The German study published
this year showed that 5-year EFS was 77±4 % in the
standard RT group and 78±4 % in the hyperfractionated RT
group [26]. The German study using adjuvant chemotherapy
concluded no difference in the survival rates in standard and
hyperfractionated groups.
Recent data of national protocols with RT and chemother-
apy are as follows: 5- and 10-year event-free survivals among
standard risk medulloblastoma were 81±2 and 75.8±2.3 %
and overall survivals were 87±1.8 and 81.3±2.1 % [27]. Even
children with high-risk medulloblastoma attain 59±10 to 71±
11 % 5-year event-free survival [28]. When compared with
our data published more than 30 years ago with only 35 %
overall survival rate, it shows that we have come a long way.
I was engaged in several biological studies. Medulloblas-
tomas were known to disseminate through the CSF pathway.
Chang’s classification published in 1969 remains active, but
it is a postoperative evaluation. I thought it was imperative to
know the incidence of spontaneous dissemination of medul-
loblastoma. Therefore, my idea was to harvest and test the
samples of the CSF and arachnoid membrane from the cister-
na magnum before tumor manipulation at the time of posterior
fossa craniotomy [29]. Subsequent data with greater number
of patients than previous publication showed that 25 of 56
CSF cytologies and 23 of 57 arachnoid biopsies were positive,
and 35 (56 %) of 63 tested were positive for tumor dissemi-
nation [30]. More recently, Souweidane et al. performed a
similar study and noted that arachnoid infiltration and CSF
cytology were found in 20.0 and 44.8 %, respectively, for
medulloblastoma/pineoblastoma (primitive neuroectodermal
tumor) [31]. Therefore, it is well justified to treat the entire
neuroaxis of medulloblastoma patients.
In the middle of the 1980s, we reviewed with Dr. Katsushi
Taomoto, a visiting neurosurgeon from Kobe, our archival
tissues of medulloblastoma and noted that certain histological
features do correlate with the patient’s outcome. It was pub-
lished in 1987 [32]. Around that time, only classic and
desmoplastic types were common prognostic indicators. Our
study disclosed pleomorphism, high nuclear/cytoplasmic ratio,
mitotic index, and high vascularity indicating poorer patient
outcome. Our observation was similar as later findings of
anaplastic and large cell medulloblastomas sub-classified by
“2007 WHO Classification of CNS Tumours” to be high-risk
medulloblastomas.
In the 1980s, in the pediatric oncology arena, DNA ploidy
was considered to be an important prognostic factor for com-
mon childhood cancers such as neuroblastoma and lympho-
blastic leukemia. The group of DNA aneuploidy fared better
than diploid type among these tumors. Because of curiosity as
to if medulloblastoma follows the same trend, we tested the
significance of DNA ploidy for prognosis of medulloblastoma
children using flow cytometry. This idea was brought up by
then Northwestern resident, Herb Engelhard. I asked then
visiting neurosurgeon Dr. Masaharu Yasue from Jikei
University in Tokyo to conduct research on this subject at
Kenneth Bauer’s flow cytometry lab at Northwestern. The
DNA ploidy results were compared with survivals of medullo-
blastoma children who were treated with postoperative RT
alone, not with chemotherapy. It was noted the group with
DNA aneuploidy showed significantly better survival [33,
34]. However, later study with DNA ploidy and MDR gene
expression showed different results; we tested 29 patients with
medulloblastoma treated from 1987 to 1991 who received both
postoperative RT and chemotherapy. The results of this
study published in 1995 showed neither DNA ploidy
nor the extent of resection influenced the survival [35].
However, MDR expression, which is present in 55 % of
the patients, showed poor outcome (P=0.007), and sta-
tistically significant correlation was noted between MDR
expression and prognosis.
Subsequently, with more advanced cytogenetic studies, we
have done cytogenetic studies on a variety of pediatric brain
tumors. We noted in 1998 that clonal abnormalities are associ-
ated with poor prognosis. Medulloblastoma has been one of the
most studied pediatric cancers in regard to cytogenesis and its
molecular characteristics [36]. More and more cytogenetic
studies and molecular biological studies have been done exten-
sively for medulloblastomas over the past two decades. More
recently in 2011, four distinct molecular variants among
medulloblastomas were classified based upon gene ex-
pression profiles and DNA copy number aberration,
which reflected patients’ prognosis [37]. These new
findings will very likely be used for future development
of national protocol. I am sure more molecular-based
findings and therapeutic options are on the horizon.
Posteior fossa ependymoma
Over the years, we found posterior fossa ependymomas are
more difficult to manage. I still remember Luis Schut men-
tioned at one of the pediatric meetings in the early 1980s that he
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would rather see a child with medulloblastoma than
ependymoma. Although I published a paper 1988 entitled
“Benign Ependymomas of the Posterior Fossa in Childhood”
[38], the treatment results are quite unsatisfactory. The term
“benign” should not be there in the title of the paper. I empha-
sized that total resection remains the way to deliver the patient’s
best outcome. However, it is often very difficult to achieve due
to cranial nerve and brain stem involvement [39]. Previously,
we could not find statistical correlation between DNA index,
patient outcome, and histology though ependymomas are mor-
phologically highly variable tumors of potential aggressiveness
without valuable prognostic markers based upon histological
and DNA flow cytometric studies [40] However, COG collect-
ed 96 posterior fossa ependymomas treated from 1990 to 2000
and concluded anaplastic variants indeed show poor prognosis
[41]. According to this report, nearly half of the patients are
Fig. 4 Brain stem tumor model
in rat; sagittal section (left) and
axial section (right) (a). An
Aztec mini-osmotic pump is
implanted for intracerebral
chronic infusion of
chemotherapy (b). In vivo
bioluminescence images in rats
showing active tumor in rat’s
brain (c)
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younger than 3 years, had gross total resection, and had ana-
plastic variants. Even the lower risk group showed the 5-year
EFS at barely 40 %.
Chemotherapy has been used for young patients with
ependymoma with unsatisfactory responses, which has been
well recognized. At our lab, Dr. Pauline Chou studied MDR
expression. We found a much larger number, 95 %, of the
ependymomas express MDR gene [42]. It is much higher
than medulloblastomas and explains the relative lack
of chemosensitivities among ependymomas. A COG study
showed that of 35 patients, 14 (40 %) demonstrated complete
response, 6 (17 %) partial response, 10 (29 %) minor response
or stable disease, and 5 (14 %) progressive tumor growth
following cisplatin-based chemotherapy [43].
We have investigated epigenetic roles on tumor onset and
progression for ependymomas at our Falk Brain Tumor
Research Lab. Histone modification and DNA methylation
resulting in alteration of the gene expression have been inves-
tigated. Preliminary studies indicate a decrease in global levels
of methylation in ependymomas, together with further reduc-
tion in methyl cytosine levels after exposure to chemotherapy
[44]. When we observed human ependymoma tissue samples
for global Alu methylation profile, methylation levels dimin-
ish when the ependymoma becomes more aggressive. Our
data indicate that chemotherapy may induce epigenetic alter-
ations that in turn cause the tumor to be more aggressive, but
this result is tentative and obviously further testing is needed.
More recently, we have looked into the expression and
role of microRNA (miRNA) in various tumors. The
miRNAs are non-coding RNAs that can block mRNA trans-
lation and affect mRNA stability. Changes in the expression
of miRNAs have been correlated with many human cancers.
We have noted tumor-specific expression of miRNAs
among pediatric brain tumors [45].
We tested miRNA contribution to the prognosis for a
variety of pediatric brain tumors. We have examined the
expression of miRNAs in ependymomas to identify molec-
ular markers of value for clinical management. miRNAs are
non-coding RNAs that can block mRNA translation and
affect mRNA stability. We have identified certain miRNAs
that are over-expressed or down-regulated in ependymomas
[46]. The miRNA expression profiles were then correlated
with tumor location and histology and uncovered specific
miRNAs which correlate with a worse prognosis. We have
uncovered associations between the expression of specific
miRNAs which portend a worse prognosis. A cluster of
miRNAs on human chromosome 14q32 is associated with
recurrence. A higher expression of miR-432, miR-411, miR
376-a, miR-381, and miR-487b was associated with a lower
recurrence-free probability, while with miR-203, we observed
that its lower expression correlated with a trend to develop
recurrences of ependymoma. Also we studied ATRT, in which
overexpression of miR221/222 is noted [47, 48]. They may be
contributing to oncogenesis and progression of ATRT. Thus,
we reason that anti-miRNA therapy might be an option for the
treatment of these very aggressive and unresponsive tumors.
Brainstem tumors
I wrote a paper in 1984, entitled “Brain Stem Gliomas in
Childhood: Rational Approach and Treatment” [49]. The term
“rational” at that time meant “do not do the biopsy for diffuse
intrinsic pontine tumors (DIPG).” The rationale is that the
obtained sample does not necessarily represent the entire
picture of the tumor due to its heterogeneity. No biopsy has
been recommended or practiced for typical DIPG in North
America since. However, based upon neuroimaging charac-
ters, these brain stem tumors were classified into several types
like Fred Epstein and Harold Hoffman did [50]. I tried surgical
options in certain groups of brain stem tumors primarily
dividing these into pontine and extra-pontine tumors; the latter
include the cerebellar peduncle lesions [51], exophytic IV
ventricle astrocytomas [52], medullary and cervicomedullary
astrocytoma, and midbrain/cerebral peduncle tumors [53] .
Because of uniformly dismal results of DIPG after conven-
tional radiotherapy, hyperfractionated RT was done as a pilot
study conducted late in the 1980s [54]. This approach was
declared to be ineffective and abandoned. A study published
by COG using conventional RT with chemotherapy showed
no difference 12 years later.
Only late in 2012 a multicenter cooperative trial of active
tissue biopsy of DIPG began to identify gene expression of
MGMT and EGFR. Based upon the gene expression, the
treatment strategy is altered by choosing different targeted
therapy. Hopefully, a breakthrough will be found for this
dreadful disease.
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In order to explore novel therapeutic methods, we started a
project of interstitial chemotherapy for DIPG [9]. In my lab,
Drs. Yuichi Tange and Akihide Kondo from Juntendo
University, Tokyo made animal brain tumor models in rats
for a convection enhanced drug delivery system (Fig. 4a) [55,
56]. Following a relentless effort, we successfully developed a
tumor model and a chronic convection enhanced delivery
system using an Aztec mini-osmotic pump (Fig. 4b). In order
to see the tumor progression in vivo, a brainstem tumor model
using bioluminescence glioma cells was established. The pro-
gression of tumor growth in the brain stem was observed in
vivo bioluminescence images in rats (Fig. 4c). We tested the
efficacy after interstitial treatment with various chemotherapy
agents including carboplatin. Dr. Guifa Xi, who succeeded
this research project in my lab, treated them with vincristine,
and the results of efficacy and toxicity were published in 2011
[57]. For that study, first, vincristine toxicities after direct
injection to the brain stem in a rat were tested to optimize
the dosage [58]. Subsequently, rat brain stem glioblastoma
was treated with vincristine administered through convection
enhanced interstitial injection comparing with control, intra-
venous, and intraperitoneal injections. Only the convection
enhanced delivery group had survival of more than
50 % while all others died within 3 weeks. The con-
vection enhanced interstitial delivery appears to be fea-
sible in animals; however, it is too early to apply this
method to the human. Clearly, the drug and dosage
selections need to be finalized.
Summary
I have given you my humble experiences of the manage-
ments of representative pediatric brain tumors including
various aspects, from clinical to basic research. There is no
question in my mind that we have made great strides in
diagnosing and treating pediatric brain tumors over the past
four decades. Look at medulloblastoma! We are now able to
cure 80 % of these children. Unfortunately, however, not
necessarily all children live. Still these children with medul-
loblastoma need cytotoxic therapies which unavoidably
cause short or long-term side effects [59]. Could we cure
Koh-chan with recurrent craniopharyngioma or a child with
DIPG seen 40 years ago in the soap opera? I am afraid the
answer is “no.” I did not mention in this presentation about
the treatment of craniopharyngioma which still remains
controversial in terms of extent of resection: total
resection vs. limited resection followed by RT [60].
How about DIPG? There have been absolutely no
breakthroughs. Insanity, as Albert Einstein once said, “is
doing the same thing again and again and expecting
different results.” Progress in molecular biology which en-
ables us to understand tumor origin, character, genetic, and
epigenetic features is breathtaking. It is our obligation to
identify the safest and most effective therapy based upon
current scientific research.
We know that today’s acceptable therapy will likely
becomes tomorrow’s obsolete. As seen in this reflection of
a portion of my life work, some of observations or ideas
were later proven to be wrong while others have led to
newer treatment concept. Einstein also said, “Anyone who
has never made a mistake has never tried anything new.”
The problem in our profession, however, is that we cannot
make mistakes and screw up a child’s brain. So, it is so
important to conduct careful investigation in the labora-
tory and develop long-range plans and research/clinical
protocol.
I still have a lot of ideas and dreams for a better future for
the pediatric neurosurgery patient. Pediatric neurosurgery,
for me, encompasses science, art, and humility. I love my
profession, and I am honored and privileged to take care of
another person’s precious child.
I appreciate the members of ISPN who supported me as
your 40th president. And the last but not least, a special
thanks to Kathy, my wife of 31 years, who has been a terrific
partner, supporting and caring for me in very difficult times
(Fig. 5). She has raised our three wonderful sons, Tadaki,
Kenji, and Dan, while I was busy, working late most of the
time. They are the best of my life and have made my life
very rich. I am very proud to call myself “a pediatric
neurosurgeon,” but I am more proud to be their father
and her husband. Without Kathy’s presence and support,
I would not be here delivering this presidential address.
Thanks Kathy.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Shkolnik A, Tomita T, Raimondi AJ, Hahn YS, McLone DG
(1983) Work in progress. Intraoperative neurosurgical ultrasound:
localization of brain tumors in infants and children. Radiology
148:525–527
2. Soltanolkotabi M, Schoeneman ME, Alden TD, Hurley MC, Ansaril
SA, DiPatri AJ, Tomita T, Shaibani A (2012) Safety and efficacy of
onyx embolization of intracranial arteriovenous malformations in
pediatric patients. J Neurosurg (Pediatr) 71(4):773–784
3. Navarro R, Gil-Parra R, Reitman AJ, Olavarria G, Grant JA,
Tomita T (2005) Endoscopic third ventriculostomy: early and
late complications and their avoidance. Childs Nerv Syst
22:506–513
4. Tomita T, Bailes J, McLone DG (1987) Giant cerebral hemispheric
tumors in childhood. Concept Pediatr Neurosurg 7:58–71
5. Tomita T, Naidich TP (1987) Successful resection of choroid
plexus papillomas diagnosed at birth: report of two cases.
Neurosurgery 20:774–779
1412 Childs Nerv Syst (2013) 29:1403–1414
6. Kalapurakal JA, Goldman S, Stellpflug W, Curran J, Sathiaseelan
V, Marymont MH, Tomita T (2006) Phase I study of intraoperative
radiotherapy with photon radiosurgery system in children with
recurrent brain tumors: preliminary report of first dose level
(10 Gy). Int J Radiat Oncol Biol Phys 65(3):800–808
7. Silva MM, Goldman S, Tomita T (2000) Optic pathway/hypotha-
lamic gliomas in children under three years of age: the role of
chemotherapy. Pediatr Neurosurg 33:151–158
8. Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Frever DR,
Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH,
Pollack IF (2012) Randomized study of two chemotherapy regi-
mens for treatment of low-grade glioma in young children: a report
from the Children’s Oncology Group. JCO 30:2641–2647
9. Tomita T (1991) Interstitial chemotherapy for brain tumors: re-
view. J Neuro Oncol 10:57–74
10. RaimondiAJ, Tomita T (1981)Hydrocephalus and infratentorial tumors.
Incidence, clinical picture and treatment. J Neurosurgery 55:174–182
11. Tomita T, Rosenblatt SS (1991) Management of hydrocephalus
secondary to posterior fossa tumor in childhood. In: Matsumoto S,
Tamaki N (eds) Hydrocephalus: pathogenesis and treatment.
Springer, Tokyo, pp 306–310
12. Raimondi AJ, Tomita T (1983) Brain tumors during the first year
of life. Child's Brain 10:193–207
13. Tomita T, McLone DG (1985) Brain tumors during the first 24
months of life. Neurosurgery 17:913–919
14. Tomita T, Raimondi AJ (1982) IV ventricle tumors. In: McLaurin
R, Reigel D, Hendrick B (eds) Pediatric neurosurgery. Grune and
Stratton, New York, pp 383–393
15. Raimondi AJ, Tomita T (1979) Medulloblastoma in childhood:
comparative results of partial and total resection. Child's Brain
5:310–328
16. Tomita T, Goldman S, Marymont M, Keating G, DeLeon G (2003)
Childhood medulloblastoma: review of 20 years’ experience.
Child Nerv Syst 19:623
17. Robertson PL, Muraszko KM, Holmes EJ, Sposto R, Packer RJ,
Gajjar A, Dias MS, Allen JC (2006) Incidence and severity of
postoperative cerebellar mutism syndrome in children with medul-
loblastoma: a prospective study by the Children’s Oncology
Group. J Neurosurg 105(6 Suppl Pediatric):444–451
18. Tomita T (1992) Long term effects of treatment for childhood brain
tumors. Neurosurg Clin North Am 3:959–971
19. Grenier Y, Tomita T, Byrd SE, Burrowes DM, Marimond M (1998)
Late post-radiation occlusive vasculopathy in childhood medullo-
blastoma: report of 2 cases. J Neurosurg 89:460–464
20. Raimondi AJ, Tomita T (1979) The disadvantages of prophylactic
whole CNS postoperative radiation therapy for medulloblastoma.
In: Paoletti P et al (eds) Multidisciplinary aspects of brain tumor
therapy. Elsevier, New York, pp 209–219
21. Hirsch JF, Renier D, Czernichow P et al (1979) Medulloblastoma in
childhood. Survival and functional results. Acta Neurochir 48:1–15
22. Tomita T, McLone DG (1986) Medulloblastoma in childhood.
Results of radical resection and low dose radiation therapy. J
Neurosurg 64:238–242
23. Thomas PRM et al (2000) Low-stage medulloblastoma: final anal-
ysis of trial comparing standard-dose with reduced-dose neuraxis
irradiation. JCO 18:3004–3011
24. Marymont MH, Geohas J, Tomita T, Strauss L, Brand WN, Mittal
BB (1996) Hyperfractionated craniospinal radiation in medullo-
blastoma. Pediatr Neurosurg 24:178–184
25. Carrie C, Grill J, Figarella-Branger D, Bernier V, Padovani L,
Habrand JL, Benhassel M, Mege M, Mahé M, Quetin P, Maire
JP, Baron MH, Clavere P, Chapet S, Maingon P, Alapetite C,
Claude L, Laprie A, Dussart S (2009) Online quality control,
hyperfractionated radiotherapy alone and reduced boost volume
for standard risk medulloblastoma: long-term results of MSFOP98.
J Clin Oncol 27(11):1879–1883
26. Lannering B, Rutkowski S, Pizer B, Gustafsson G, Navajas A,
Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R,
Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T,
Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-
Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012)
Hyperfractionated versus conventional radiotherapy followed by
chemotherapy in standard-risk medulloblastoma: results from the
randomized multicenter HIT-SIOP PNET 4 Trial. J Clin Oncol
30(26):3187–3193
27. Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A (2013) Survival
and secondary tumors in children with medulloblastoma receiving
radiotherapy and adjuvant chemotherapy: results of Children’s
Oncology Group Trial A9961. Neurooncol 15(1):97–103
28. Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A,
Goldwein J, Mehta M, Packer RJ, Tarbell N, Fitz C, Vezina G,
Hilden J, Pollack IF (2012) Outcome of children with metastatic
medulloblastoma treated with carboplatin during craniospinal ra-
diotherapy: a Children's Oncology Group Phase I/II study. J Clin
Oncol 30(21):2648–2653
29. Tomita T, McLone DG (1983) Spontaneous seeding of medullo-
blastoma: results of CSF cytology and arachnoid biopsy from the
cisterna magnum. Neurosurgery 12:265–267
30. Tomita T, Marymont M, Strauss L, La Marca F (1997) Childhood
medulloblastomas: spontaneous disseminations, pattern of recur-
rences and importance of adjuvant chemotherapy. Neurol Surg
Relaz 11:163–168
31. Souweidane MM, Morgenstern PF, Christos PJ, Edgar MA,
Khakoo Y, Rutka JT, Dunkel IJ (2009) Intraoperative arachnoid
and cerebrospinal fluid sampling in children with posterior fossa
brain tumors. Neurosurgery 65(1):72–78
32. Taomoto K, Tomita T, Raimondi AJ, Leestma JE (1987)
Medulloblastoma in childhood: histological factors influencing
the patients’ outcome. Child's Nervous System 3:354–360
33. Tomita T, Yasue M, Engelhard H, Bauer KD, McLone DG,
Gonzalez Crussi F (1988) Flow cytometric DNA analysis of me-
dulloblastoma: correlation between DNA ploidy and outcome.
Cancer 61:744–749
34. Yasue M, Tomita T, Engelhard H, Gonzalez Crussi F, McLone DG,
Bauer KD (1989) Prognostic importance of DNA ploidy in me-
dulloblastoma of childhood. J Neurosurg 70:385–391
35. Chou PM, Reyes Mugica M, Braquin N, Yasuda T, Tan X, Tomita
T (1995) Multidrug resistance gene expression in childhood me-
dulloblastoma: correlation with clinical outcome and DNA ploidy
in 29 patients. Pediatr Neurosurg 23:283–291
36. Tomita T (1996) Medulloblastoma. In: Youmans JR et al (eds)
Neurological surgery (4th ed.). Saunders, Philadelphia, pp 2570–2592
37. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G,
Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S,
Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopath-
ological correlates of SHH, WNT, and non-SHH/WNT molecular
subgroups. Acta Neuropathol 121(3):381–396
38. Tomita T, McLone DG, Das L, Brand WN (1988) Benign
ependymomas of the posterior fossa in childhood. Pediatr
Neurosci 14:277–285
39. Tomita T (2001) Ependymomas. In: McLone DG (ed) Pediatric
neurosurgery. Saunders, Philadelphia, pp 822–834
40. Reyes-Mugica M, Chou PM, Myint MM, Ridaura-Sanz C,
Gonzalez-Crussi F, Tomita T (1994) Ependymomas in children:
histological and DNA-flow cytometric study. Pediatrc Pathol
14:453–466
41. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ
(2008) The prognostic value of histological grading of posterior fossa
ependymomas in children: a Children's Oncology Group study and a
review of prognostic factors. Mod Pathol 21(2):165–177
42. Chou PM, Barquib N, Yasuda T, Sanz CR, Gonzalez Crussi F,
Tomita T (1996) Ependymomas express the multidrug resistance
Childs Nerv Syst (2013) 29:1403–1414 1413
gene: immunohistochemical and molecular biologic study. Pediat
Pathol Lab Med 16:551–561
43. Garvin JH Jr, Selch MT, Holmes E, Berger MS, Finlay JL, Flannery
A, Goldwein JW, Packer RJ, Rorke-Adams LB, Shiminski-Maher T,
Sposto R, Stanley P, Tannous R, Pollack IF (2012) Children's
Oncology Group. Phase II study of pre-irradiation chemotherapy
for childhood intracranial ependymoma. Children's Cancer Group
protocol 9942: a report from the Children's Oncology Group.
Pediatr Blood Cancer 59(7):1183–1189
44. Xie H, Wang M, de Fatima Bonaldo M, Rajaram V, Stellpflug W,
Smith C, Kelly Arndt K, Goldman S, Tomita T, Soares M (2010)
Epigenomic analysis of Alu repeats in human ependymomas. Proc
Natl Acad Sci 107(15):6952–6957
45. Sredoni S, Huang CC, Bonaldo M, Tomita T (2011) MicroRNA
expression profiling for molecular classification of pediatric brain
tumor. Pediatric Blood Cancer 57:183–184
46. Costa FF, Bischof JM, Rishi R, Lula RR, Wang M, Sredni SS,
Rajaram V, Bonaldo MF, Vanin EF, Wang D, Goldman S, Tomita
T, Soares MB (2011) Identification of microRNAs as potential prog-
nostic markers in ependymoma. Public Libr Sci One 6(10):e25114
47. Sredni ST, Bonaldo M, Costa FF, Huang C-C, Hamm C, Rajaran V,
Tomita T, Goldman S, Bischof J, Soares MB (2010) Upregulation of
Mir 221 andMir 222 in atypical/teratoid tumors/potential therapeutic
target. Childs Nerv Syst 26:279–283
48. Sredoni S, Huang CC, de Bonaldo MF, Tomita T (2011)
MicroRNA expression profiling for molecular classification of
pediatric brain tumors. Pediatr Blood Cancer 57(1):183–184
49. Tomita T, McLone DG, Naidich TP (1984) Brain stem gliomas in
childhood. Rational approach and treatment. J Neuro-Oncology 2:117–
122
50. Tomita T, Radkowski MA, Chaddia A (1990) Brain stem tumors in
childhood; Correlation of CT findings with patients' outcome.
Concepts Pediatric Neurosurg 10:78–96
51. Tomita T (1986) Surgical management of cerebellar peduncle
lesions in childhood. Neurosurgery 18:568–575
52. Tomita T, Chou P, Reyes Mugica M (1998) Fourth ventricle
astrocytomas: clinicopathological analysis of 21 cases. Childs
Nerv Syst 14:537–546
53. Tomita T, Cortes RF (2002) Astrocytomas of the cerebral peduncle
in children: surgical experience of seven patients. Childs Nerv Syst
18:225–230
54. Packer RJ, Allen JC, Goldwein JL, Newall J, Zimmerman RA,
Priest J, Tomita T, Mandelbaum DE, Cohen BH, Finlay JL, Sutton
LN, D’Angio G (1990) Hyperfractionated radiotherapy for chil-
dren with brainstem gliomas: a pilot study using 7,200 cGy. Ann
Neurol 27:167–173
55. Tange Y, Daneriallis DM, Kondo A, Mania-Farnell B, Nakazaki H,
Rajaram V, Goldman S, Egorin MJ, Soares MB, Tomita T (2009)
Interstitial continuous infusion therapy in a malignant glioma
model in rats. Childs Nerv Syst 25:655–662
56. Kondo A, Goldman S, Vanin EF, Sredni ST, Rajaram V, Soares MB,
Tomita T (2009) An experimental brainstem tumor model using in
vitro bioluminescence imaging in rat. Childs Nerv Syst 25:527–533
57. Xi G, Mania-Farnell B, Veena Rajaram V, Mayanil C, Soares MS,
Tomita T, Goldman S (2012) Efficacy of interstitial continuous
vincristine infusion in a bioluminescent rodent intracranial tumor
model. J Neurooncology 106(2):261–270
58. Xi G, Tomita T, Rajaram V, Mania-Farnell B, Ichi S, Mayanil SC,
Soares MB, Goldman S (2012) Efficacy of vincristine adminis-
tered via convection-enhanced delivery in a rodent brainstem tu-
mor model documented by bioluminescence imaging. Childs Nerv
Syst 28(4):565–574
59. Ris MD, Walsh K, Wallace D, Armstrong FD, Holmes E, Gajjar A,
Zhou T, Packer RJ (2013) Intellectual and academic outcome
following two chemotherapy regimens and radiotherapy for
average-risk medulloblastoma: COG A9961. Pediatr Blood
Cancer. doi:10.1002/pbc.24496
60. Tomita T, Bowman RM (2005) Craniopharyngiomas in children:
surgical experience at Children’s Memorial Hospital. Child’s Nerv
Syst 21:729–746
1414 Childs Nerv Syst (2013) 29:1403–1414
